original ) (raw )Quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine (MenACWY-TT): a review
Ghassan Dbaibo
Expert Opinion on Biological Therapy, 2013
View PDFchevron_right
Epidemiology and prevention of meningococcal disease: a critical appraisal of vaccine policies
M. Safadi
Expert Review of Vaccines, 2011
View PDFchevron_right
Safety, Reactogenicity, and Immunogenicity of a Tetravalent Meningococcal Polysaccharide–Diphtheria Toxoid Conjugate Vaccine Given to Healthy Adults
Jacek Wysocki
The Journal of Infectious Diseases, 2002
View PDFchevron_right
Priorities for research on meningococcal disease and the impact of serogroup A vaccination in the African meningitis belt
D. Caugant , Claire Broome
Vaccine, 2013
View PDFchevron_right
Safety and Immunogenicity of a Tetravalent Polysaccharide Vaccine Against Meningococcal Disease
Luan-yin Chang , Yu Chia Hsieh
Journal of the Formosan Medical Association, 2009
View PDFchevron_right
The changing and dynamic epidemiology of meningococcal disease
Mary Ramsay
Vaccine, 2012
View PDFchevron_right
Vaccines for the prevention of meningococcal disease in children
M. Soriano-gabarró
Seminars in Pediatric Infectious Diseases, 2002
View PDFchevron_right
Meningococcal disease: public health burden and control
MARIA JOSE SANTAMARIA HERGUETA
World health statistics quarterly. Rapport trimestriel de statistiques sanitaires mondiales, 1997
View PDFchevron_right
Editorial Commentary: The Endgame for Serogroup A Meningococcal Disease in Africa?
Martin Maiden
Clinical Infectious Diseases, 2013
View PDFchevron_right
Meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine: a new conjugate vaccine against invasive meningococcal disease
Ghassan Dbaibo
Infection and Drug Resistance, 2014
View PDFchevron_right
Critical analysis of old and new vaccines against N. meningitidis serogroup C, considering the meningococcal disease epidemiology in Brazil
Lucia Bricks
REVISTA-HOSPITAL DAS CLINICAS FACULDADE DE …, 2003
View PDFchevron_right
A review of vaccine research and development: Meningococcal disease☆
maria constanza aguado
Vaccine, 2006
View PDFchevron_right
Changes in Serogroup and Genotype Prevalence Among Carried Meningococci in the United Kingdom During Vaccine Implementation
Jenny Maclennan
Journal of Infectious Diseases, 2011
View PDFchevron_right
An overview of the meningococcal disease and impact of the quadrivalent meningococcal conjugate vaccine
Jehan Alrahimi
Novel Research in Microbiology Journal, 2021
View PDFchevron_right
Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study
Mark Alderson
The Lancet. Infectious diseases, 2018
View PDFchevron_right
Meningococcal Disease: Epidemiology and Early Effects of Immunization Programs
eitan berezin
Journal of the Pediatric Infectious Diseases Society, 2014
View PDFchevron_right
Molecular epidemiology of meningococcal disease in England and Wales 1975-1995, before the introduction of serogroup C conjugate vaccines
Martin Maiden
Microbiology, 2008
View PDFchevron_right
Meningococcal disease
Ziad Memish
Saudi medical journal, 2002
View PDFchevron_right
The immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tetravalent polysaccharide vaccine
Noel Macalalad , Mari Rose Aplasca-de Los Reyes
Human Vaccines & Immunotherapeutics, 2012
View PDFchevron_right
Meningococcal carriage in young adults six years after meningococcal C conjugate (MCC) vaccine catch-up campaign in Salvador, Brazil
Ítalo Ferreira
Vaccine, 2020
View PDFchevron_right
Cochrane review: Conjugate vaccines for preventing meningococcal C meningitis and septicaemia
lucieni conterno
Evidence-Based Child Health: A Cochrane Review Journal, 2007
View PDFchevron_right
Meningococcal vaccines: past, present, and future perspectives
Seyed Davar Siadat
View PDFchevron_right
Update on Meningococcal Disease with Emphasis on Pathogenesis and Clinical Management
Petter Brandtzæg
Clinical Microbiology Reviews, 2000
View PDFchevron_right
Critical appraisal of a quadrivalent CRM197 conjugate vaccine against meningococcal serogroups A, C W-135 and Y (Menveo®) in the context of treatment and prevention of invasive disease
Lisa DeTora
Infection and Drug Resistance, 2011
View PDFchevron_right
Influence of Serogroup on the Presentation, Course, and Outcome of Invasive Meningococcal Disease in Children in the Republic of Ireland, 1995–2000
Owen Hensey
Clinical Infectious Diseases, 2002
View PDFchevron_right
The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine
Sven Arne Silfverdal
International Journal of Infectious Diseases, 2012
View PDFchevron_right
Preclinical Studies and Clinical Trials in Determination of Safety and Efficacy of Meningococcal Vaccines: Present Scenario
sutapa biswas majee
Asian Journal of Pharmaceutical and Clinical Research, 2021
View PDFchevron_right